Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Sign up for GitHub

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

QPPSE-3302: Set USWR32 to single rate for PY24 #886

Merged
merged 3 commits into from
Jan 6, 2025
Merged

QPPSE-3302: Set USWR32 to single rate for PY24 #886

Show file tree
Hide file tree
Changes from all commits
Commits
Show all changes
3 commits
Select commit Hold shift + click to select a range
78473f1
QPPSE-3302: Set USWR32 to single rate for PY24
pkasarski Jan 6, 2025
a921172
Fix newline
pkasarski Jan 6, 2025
aac6d8c
feat: QPPSE-3302 update staging file
ckawell Jan 6, 2025
File filter

Filter by extension

Filter by extension
Conversations
Failed to load comments.
Loading
Jump to
Jump to file
Failed to load files.
Loading
Diff view
Diff view
2 changes: 1 addition & 1 deletion benchmarks/2024.json
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -6920,7 +6920,7 @@
"isToppedOut": false,
"isHighPriority": true,
"isInverse": false,
"metricType": "registryMultiPerformanceRate",
"metricType": "registrySinglePerformanceRate",
"isToppedOutByProgram": false,
"percentiles": {
"1": 9.81,
Expand Down
2 changes: 1 addition & 1 deletion staging/2024/benchmarks/benchmarks.csv
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -226,5 +226,5 @@ Use of Thyroid Imaging Reporting & Data System (TI-RADS) in Final Report to Stra
Repeat screening or surveillance colonoscopy recommended within one year due to inadequate/poor bowel preparation,NHCR4,QCDR Measure,Process,23.728824017369927,79.26,No,No,9.52,44.5,61.9,73.91,82.61,88.33,95.3,96.15,100.0,100.0,100.0,Y,N,registrySinglePerformanceRate
Oncology: Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs,PIMSH10,QCDR Measure,Process,24.469886675299424,55.58,No,No,4.9,16.0,38.2,43.9,48.1,57.95,61.8,71.1,81.8,88.0,95.7,Y,N,registrySinglePerformanceRate
Screening for Osteoporosis for Men Aged 70 Years and Older,UREQA9,QCDR Measure,Process,15.246750637430914,20.80,No,No,0.22,2.6,7.97,11.925,13.81,20.305,23.695,26.995,33.57,34.71,64.71,N,N,registrySinglePerformanceRate
Adequate Compression at each visit for Patients with Venous Leg Ulcers (VLUs) appropriate to arterial supply,USWR32,QCDR Measure,Intermediate Outcome,24.985232817553815,76.40,No,No,9.81,31.23,68.85,78.785,79.465,82.765,87.095,91.255,94.615,96.275,97.56,Y,N,registryMultiPerformanceRate
Adequate Compression at each visit for Patients with Venous Leg Ulcers (VLUs) appropriate to arterial supply,USWR32,QCDR Measure,Intermediate Outcome,24.985232817553815,76.40,No,No,9.81,31.23,68.85,78.785,79.465,82.765,87.095,91.255,94.615,96.275,97.56,Y,N,registrySinglePerformanceRate
Vitamin D level: Effective Control of Low Bone Mass/Osteopenia and Osteoporosis: Therapeutic Level Of 25 OH Vitamin D Level Achieved,UREQA8,QCDR Measure,Outcome,26.30521779339405,45.75,No,No,0.21,6.405,23.29,33.59,38.9,43.335,52.1,64.04,68.195,84.51,86.04,Y,N,registrySinglePerformanceRate
2 changes: 1 addition & 1 deletion staging/2024/benchmarks/json/benchmarks.json
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -5682,7 +5682,7 @@
"isToppedOut": false,
"isHighPriority": true,
"isInverse": false,
"metricType": "registryMultiPerformanceRate",
"metricType": "registrySinglePerformanceRate",
"isToppedOutByProgram": false,
"percentiles": {
"1": 9.81,
Expand Down
Loading